WEBULL
WebtradeDownload

Protagonist Therapeutics (PTGX) Could Be 18% Undervalued As Earnings Expectations Rise

Simply Wall St · 1d ago

Earnings Expectations Put Protagonist Therapeutics Under the Spotlight

Protagonist Therapeutics (PTGX) heads into its upcoming quarterly report with attention firmly on earnings. The consensus points to earnings of $2.58 per share and a very large year over year jump, alongside higher projected revenue.

Recent trading in Protagonist Therapeutics has been choppy in the short term, with the share price slipping about 2% over the past 90 days even as it gained roughly 2% over 30 days and 64% year to date. At the same time, the 1 year total shareholder return of 84% and 3 year total shareholder return of almost 8x suggest momentum has been strong over a longer stretch as investors reassess both growth potential and risk around its pipeline and upcoming earnings profile.

Scan beyond Protagonist Therapeutics and line up other fast moving biopharma stories using our curated list of 19 high quality undiscovered gems as a starting point.

After a 64% year to date jump and an almost 8x three year return, Protagonist Therapeutics now sits at a crossroads. Is the meaningful upside still ahead, or has the rerating already done most of the work?

Most Popular Narrative: 18% Undervalued

On the most followed narrative, Protagonist Therapeutics screens as undervalued, with a fair value of $174.69 against a last close of $143.37, which puts a lot of attention on whether its pipeline can keep justifying that gap.

The main requirement for the strategy to succeed is effective execution on oral peptide programs such as PN‑881 and obesity incretin agonists, so that the platform yields additional clinically and commercially relevant drugs beyond the two approved assets.

The current valuation suggests the market is assigning limited value to Protagonist Therapeutics beyond existing ICOTYDE and MIMRYLO economics, despite the company’s shift to profitability, sizeable cash balance, and a new US$300 million share repurchase program.

See why 3 investors see Protagonist Therapeutics as 18% undervalued.

Result: Fair Value of $174.69 (UNDERVALUED)

Still, the narrative can crack if ICOTYDE or MIMRYLO royalties fall short of assumptions, or if Protagonist Therapeutics trades on a lower P/E than analysts project.

Find out about the key risks to this Protagonist Therapeutics narrative.

Another Angle On Protagonist Therapeutics Valuation

While the fair value narrative points to Protagonist Therapeutics trading below a $174.69 target, the P/E tells a very different story. The stock changes hands at 111.9x earnings, compared with 19.6x for the US Biotechs group and 45x for peers, and a fair ratio of 28.1x. That kind of gap can reward believers if earnings keep up, but it also leaves less room for error. Which signal do you trust more when the next few quarters land?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:PTGX P/E Ratio as at Nov 2026
NasdaqGM:PTGX P/E Ratio as at Nov 2026

Next Steps

Feeling the mixed signals in Protagonist Therapeutics right now is normal, especially with valuation and earnings telling slightly different stories. If you want to move quickly and build your own view from the ground up, start with the 4 key rewards.

Looking For More Investment Ideas Beyond Protagonist Therapeutics?

If Protagonist Therapeutics has sharpened your thinking on risk and reward, you can use that momentum to sift through fresh ideas tailored to your own style and constraints.